Iradimed Q3 2023 Earnings Report $54.65 +1.30 (+2.44%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Iradimed EPS ResultsActual EPS$0.40Consensus EPS $0.34Beat/MissBeat by +$0.06One Year Ago EPSN/AIradimed Revenue ResultsActual Revenue$16.51 millionExpected Revenue$16.21 millionBeat/MissBeat by +$300.00 thousandYoY Revenue GrowthN/AIradimed Announcement DetailsQuarterQ3 2023Date11/3/2023TimeN/AConference Call ResourcesPress ReleaseIRMD Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Iradimed Earnings HeadlinesIRADIMED CORPORATION to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 19 at 8:30 AM | globenewswire.comShould You Investigate IRADIMED CORPORATION (NASDAQ:IRMD) At US$54.43?December 13, 2024 | uk.finance.yahoo.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 22, 2024 | Behind the Markets (Ad)IRADIMED CORPORATION on Forbes’ List of America’s Most Successful Small-Cap Companies for 2025December 10, 2024 | markets.businessinsider.comIRADIMED CORPORATION on Forbes' List of America's Most Successful Small-Cap Companies for 2025December 10, 2024 | globenewswire.comiRadimed (NASDAQ:IRMD) Stock Quotes, Forecast and News SummaryDecember 4, 2024 | benzinga.comSee More Iradimed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Iradimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your email. Email Address About IradimedIradimed (NASDAQ:IRMD) develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.View Iradimed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
